Skip Navigation LinksHome > June 2013 - Volume 23 - Issue 5 > CA-125 Level as a Prognostic Indicator in Type I and Type II...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e31828f7a24
Ovarian Cancer

CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer

Chen, Xiaoxiang MD, PhD*†‡; Zhang, Jing MD, PhD*††; Cheng, Wenjun MD, PhD§; Chang, Doo Young MD*; Huang, Jianfei MD, PhD*; Wang, Xuan MS*∥; Jia, Lizhou MD*; Rosen, Daniel G. MD; Zhang, Wei PhD*; Yang, Da PhD*; Gershenson, David M. MD#; Sood, Anil K. MD, PhD#; Bast, Robert C. Jr MD**; Liu, Jinsong MD, PhD*

Supplemental Author Material
Collapse Box

Abstract

Objective: Most patients with epithelial ovarian cancer achieve a complete clinical remission (CCR) with normal CA-125 but will still relapse and die from their disease. The present study was designed to determine whether CA-125 levels before, during, and after primary treatment provide prognostic information for both type I and type II ovarian cancer.

Methods: In this retrospective study, we identified 410 patients with epithelial ovarian cancer who had achieved a CCR between 1984 and 2011. A Cox proportional hazards model and log-rank test were used to assess associations between the nadir CA-125, histotype, and prognosis.

Results: The baseline serum CA-125 concentration was higher in patients with type II ovarian cancer than in those with type I ovarian cancer (P < 0.001). The nadir CA-125 was an independent predictor of progression-free survival (PFS; P < 0.001) and overall survival (OS; P = 0.035) duration. The PFS and OS durations were 21.7 and 79.4 months in patients with CA-125 of 10 U/mL or less and 13.6 and 64.6 months in those with CA-125 of 11 to 35 U/mL, respectively (P = 0.01 and P = 0.002, respectively). Histotype was an independent predictor of PFS (P = 0.041): the PFS and OS durations of the patients with type I ovarian cancer were longer than those of the patients with type II ovarian cancer (P < 0.001 and P < 0.001, respectively).

Conclusions: The nadir CA-125 and histotype are predictive of PFS and OS durations in patients with ovarian cancers who experienced a CCR. Progression-free survival and OS durations were shorter in the patients with CA-125 levels of 11 to 35 U/mL and type II disease than in those with CA-125 levels of 10 U/mL or less and type I ovarian cancer.

Copyright © 2013 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.